ZymoGenetics, Seattle Biotech Pioneer, Acquired by Bristol-Myers for $885 Million

The M&A market continues to pick up steam.

Mark Hurd May Not Be the Answer for Oracle

The database king wasn't always this stable.

Alt Energy Needs Alt Financing

The expiration of federal grants may doom more alt-energy projects.

Don't Let Stress-Test Critics Talk You Out of Good Stocks

Many banks didn't include full disclosures about their debt.

How Much of a Bargain Is Frontier Communications Right Now?

Let's take a look.

Category: Uncategorized

More Feeds